In this study, we identified auranofin, an FDA-approved anti–rheumatoid arthritis agent, as a TOPBP1 inhibitor with high potency in disrupting the interaction of TOPBP1 with PHF8 and FANCJ by docking to the hydrophobic pocket of BRCT 7–8. This evidence concerns the gene TOPBP1 and rheumatoid arthritis.